Federated Hermes, Inc. Hookipa Pharma Inc. Transaction History

Federated Hermes, Inc.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.71 - $1.97 $959 - $2,663	-1,352 Reduced 65.63%	708 $0
Q1 2023 May 08, 2023	SELL	$0.72 - $1.03 $460 - $658	-639 Reduced 23.68%	2,060 $1,000
Q4 2022 Feb 13, 2023	SELL	$0.73 - $14.6 $499 - $9,986	-684 Reduced 20.22%	2,699 $2,000
Q3 2022 Nov 14, 2022	BUY	$1.27 - $15.0 $1,055 - $12,465	831 Added 32.56%	3,383 $5,000
Q2 2022 Aug 15, 2022	SELL	$1.33 - $2.31 $1,171 - $2,035	-881 Reduced 25.66%	2,552 $4,000
Q1 2022 May 13, 2022	SELL	$1.26 - $2.52 $241,831 - $483,663	-191,930 Reduced 98.24%	3,433 $8,000
Q4 2021 Feb 14, 2022	BUY	$2.33 - $5.94 $43,324 - $110,448	18,594 Added 10.52%	195,363 $455,000
Q3 2021 Nov 15, 2021	SELL	$5.89 - $9.35 $425,340 - $675,200	-72,214 Reduced 29.0%	176,769 $1.04 Million
Q2 2021 Aug 16, 2021	BUY	$9.16 - $19.51 $2 Million - $4.25 Million	218,019 Added 704.1%	248,983 $2.28 Million
Q1 2021 May 13, 2021	BUY	$10.64 - $14.7 $329,456 - $455,170	30,964 New	30,964 $416,000
Q2 2020 Aug 13, 2020	SELL	$7.23 - $12.1 $2,696 - $4,513	-373 Closed	0 $0
Q1 2020 May 13, 2020	BUY	$5.9 - $13.8 $2,200 - $5,147	373 New	373 $3,000

677K

Ticker HOOK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,654,500
Market Cap $98.7M
Description
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transpl...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.